Compare XENE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | LQDA |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2014 | 2018 |
| Metric | XENE | LQDA |
|---|---|---|
| Price | $43.91 | $31.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $53.91 | $37.40 |
| AVG Volume (30 Days) | 754.3K | ★ 1.1M |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,500,000.00 | ★ $69,216,000.00 |
| Revenue This Year | N/A | $994.17 |
| Revenue Next Year | N/A | $169.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 343.41 |
| 52 Week Low | $26.74 | $11.26 |
| 52 Week High | $46.60 | $36.41 |
| Indicator | XENE | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 43.69 |
| Support Level | $43.41 | $33.45 |
| Resistance Level | $46.36 | $35.20 |
| Average True Range (ATR) | 1.32 | 1.54 |
| MACD | -0.11 | -0.51 |
| Stochastic Oscillator | 37.28 | 9.59 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.